Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Peripheral blood or bone marrow grafts for unrelated donors with posttransplant cyclophosphamide-based graft-versus-host disease prophylaxis

Leonardo Arcuri, Victor Natal, Mariana Kerbauy et al. Nov 03, 2025 pp. 6002-6002 10.1182/blood-2025-6002

Abstract Introduction Peripheral blood (PB) grafts are a well-known risk factor for graft-versus-host disease (GVHD) in...

The enrichment of T-regulatory cells as a potential therapeutic approach for cerebral vasculopathy in sickle cell disease

Paritosh Mondal, Shane Lenhart, Lesley Foley et al. Nov 03, 2025 pp. 10-10 10.1182/blood-2025-10

Abstract Cerebral vasculopathy is a major contributor to morbidity and mortality in sickle cell disease (SCD). The complex interactions betw...

Social determinants of health and outcomes of bone marrow transplantation in patients with aplastic anemia: A 23-year retrospective cohort study

Phuong Vo, Salene Jones, Alireza Ebrahimi et al. Nov 03, 2025 pp. 2686-2686 10.1182/blood-2025-2686

Abstract Introduction: Bone marrow transplantation (BMT) outcomes in patients with aplastic anemia (AA) have significantly improved during t...

Characteristics and treatment patterns of nontransplanted patients with newly diagnosed multiple myeloma treated with daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRd) or daratumumab, lenalidomide, and dexamethasone (DRd) in the frontline setting

Sikander Ailawadhi, Xin Yin, Eric Chinaeke et al. Nov 03, 2025 pp. 6359-6359 10.1182/blood-2025-6359

Abstract Introduction: DRd is the standard of care for frontline (FL) treatment (tx) of transplant-ineligible (TIE) patients with newly diag...

Estimating incident and prevalent essential thrombocythemia patients eligible for cytoreductive therapies in the US and Canada

Paul Walden, Craig Zimmerman, Noemi Hummel et al. Nov 03, 2025 pp. 8199-8199 10.1182/blood-2025-8199

Abstract Introduction: Essential thrombocythemia (ET) is a rare type of myeloproliferative neoplasm (MPN) characterized by elevated platelet...

Multiple myeloma in adolescents and young adults (AYA): A comparative analysis of global and u.S.a, epidemiological trends, risk factors, and projections (1990–2040)

Rupayan Kundu, Kriti Soni, Niladri Kal et al. Nov 03, 2025 pp. 5788-5788 10.1182/blood-2025-5788

Abstract Introduction: Multiple myeloma (MM), historically considered a malignancy of older adults, is increasingly bein...

Clinical characteristics and outcome of diffuse large B-cell lymphoma: Real world data from Saudi Arabia

Abdullah Alrajhi, Mohsen Alzahrani, Muhned Alhumaid et al. Nov 03, 2025 pp. 1893-1893 10.1182/blood-2025-1893

Abstract Background: Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma both globa...

Early TCR diversity and recipient stem-cell persistence predict relapse and reveal therapeutic targets after allogeneic transplantation

Nurefsan Sariipek, Ksenia Safina, Shuqiang Li et al. Nov 03, 2025 pp. 6065-6065 10.1182/blood-2025-6065

Abstract Introduction Standard treatment for high and intermediate risk acute myeloid leukemia (AML) includes induction chemotherapy followe...

Serum neurofilament light chain (NfL) as a biomarker for chemotherapy-induced peripheral neuropathy (CIPN) in pediatric acute lymphoblastic leukemia (ALL)

Giacomo Gotti, Gaia Kullmann, Chiara Zoia et al. Nov 03, 2025 pp. 3317-3317 10.1182/blood-2025-3317

Abstract CIPN is a relatively common complication in children and adolescents undergoing treatment for ALL and it is mostly associated with...

CD34 selected stem cell boost provides robust outcomes in patients with poor graft function

Sayan Mullick Chowdhury, Qiuhong Zhao, Sarah Wall et al. Nov 03, 2025 pp. 7790-7790 10.1182/blood-2025-7790

Abstract Background: Allogenic stem cell transplantation (SCT) is a curative option in several hematological malignancies. However, patients...

Efficacy and safety of benralizumab in patients with hypereosinophilic syndrome: Results from the Phase 3 natron study

Princess Ogbogu, Florence Roufosse, Praveen Akuthota et al. Nov 03, 2025 pp. 79-79 10.1182/blood-2025-79

Abstract Background: Hypereosinophilic syndrome (HES) is a group of rare, heterogeneous disorders characterized by persistent hypereosinophi...

Trial in progress: A phase I/ib dose-finding study of ropeginterferon alfa-2b (P1101) in patients with cutaneous T-cell lymphoma (CTCL)

Yumeng Zhang, Jongphil Kim, Richard Corona et al. Nov 03, 2025 pp. 1881-1881 10.1182/blood-2025-1881

Abstract Background and Significance: Cutaneous T-cell lymphoma (CTCL) is a rare, incurable non-Hodgkin lymphoma characterized by progressiv...

ST6GALNAC4 promotes DLBCL progression by regulating ldha sialylation to enhance glycolysis and lactate production

Anqi Zhou, Xinyu Yang, Guangcai Zhong et al. Nov 03, 2025 pp. 3309-3309 10.1182/blood-2025-3309

Abstract Targeted epigenetic modification has emerged as a critical strategy in cancer therapy, showing promising therapeutic potential in s...

Synergistic antitumor effects and mechanisms of KPT-330 combined with venetoclax in Acute Myeloid Leukemia

Yifan Liu, Weidong Ding, Xiaoya Yun et al. Nov 03, 2025 pp. 6104-6104 10.1182/blood-2025-6104

Abstract Introduction The venetoclax-azacitidine (VA) regimen is a standard frontline therapy for elderly or chemotherapy-ineligible patient...

Evaluation of clonal hematopoiesis and the clinical impact of myeloid somatic mutations on hematologic and marrow parameters in patients without diagnosed malignancy: A single center retrospective cohort study.

Lauren Scarpetti, Chinyere Okpara, Mihir Shukla et al. Nov 03, 2025 pp. 6707-6707 10.1182/blood-2025-6707

Abstract Background The increasing use of next-generation sequencing (NGS) has identified a subset of patients who harbor somatic mutations...

The NLP protein is a novel regulator of G2-m Phase of the cell cycle critical for proliferation of human peripheral T-cell lymphomas

Julian Tobon, Dana Koptides, Jana Opavska et al. Nov 03, 2025 pp. 5040-5040 10.1182/blood-2025-5040

Abstract Peripheral T-cell lymphomas (PTCL) are a diverse group of aggressive T- and NK-cell malignancies distinguished by differences in ce...

Establishment of a prognostic model for diffuse large B-cell lymphoma based on mitochondrial energy metabolism-related genes

Ganyu Feng, Yupiao Feng, Yutang Li et al. Nov 03, 2025 pp. 7086-7086 10.1182/blood-2025-7086

Abstract Mitochondrial energy metabolism has emerged as a critical regulator of tumor progression and immune dynamics. However, its prognost...

RNA−binding protein FXR1 stabilizes receptor tyrosine kinase FGFR1 and enhances PI3K−Akt signaling to promote T−cell leukemogenesis

Boxiao Chen, Zhaoxing Wu, Luyu Yang et al. Nov 03, 2025 pp. 5039-5039 10.1182/blood-2025-5039

Abstract Introduction: T-cell acute lymphoblastic leukemia (T-ALL) is a highly aggressive hematologic malignancy with poor five-year surviva...

Characterization of antecedent clonal hematopoiesis (CH) mutations in lymphoid and plasma cell neoplasms

Pinkal Desai, Zichan Li, Ying Li et al. Nov 03, 2025 pp. 1399-1399 10.1182/blood-2025-1399

Abstract Background: Premalignant CH pattern for myeloid malignancies is well established but the characteristics and pattern, if any, that...

Adult acute myeloid leukemia with NUP98 rearrangement benefits from targeted therapy and bone marrow transplantation

Hongming Zhu, Yunxiang Zhang, Xia Li et al. Nov 03, 2025 pp. 3391-3391 10.1182/blood-2025-3391

Abstract Introduction: Nucleoporin 98 (NUP98) rearrangement has been proposed as a type of acute myeloid leukemia (AML)...

Pulmonary vein thrombosis following bronchoscopic cryobiopsy: A case report

Sabina Dhami, Thinesh Dahanayake, Mandeep Dhami Nov 03, 2025 pp. 6663-6663 10.1182/blood-2025-6663

Abstract Pulmonary vein thrombosis (PVT) is a rare and often underdiagnosed condition typically associated with thoracic surgery, catheter a...

Updated meta-analysis of inhibitor development in previously untreated patients with severe Hemophilia A: Plasma-derived versus recombinant FVIII products

Anthony Navarrete Rios, Laith Al Khraisat, Anisha Agarwal et al. Nov 03, 2025 pp. 3071-3071 10.1182/blood-2025-3071

Abstract Background:  Neutralizing inhibitors remain the major complication of replacement therapy in previously untreated patients (PUPs) w...

Lipid metabolism disorders and immune metabolic programming in patients with idiopathic multicentric Castleman disease

Jiaying Ge, Xuejiao Yin, Yi Liu et al. Nov 03, 2025 pp. 3004-3004 10.1182/blood-2025-3004

Abstract Idiopathic multicentric Castleman disease (iMCD) is a rare hematologic disorder characterized by lymphadenopathy, with high heterog...

High levels of soluble TREM2 predict poor survival outcomes and facilitate the expansion of immunosuppressive monocytic-lineage cells in patients with DLBCL.

Hao-Yuan Wang, Po-Chun Liu, Fu-Chen Yang et al. Nov 03, 2025 pp. 3659-3659 10.1182/blood-2025-3659

Abstract Introduction : Triggering receptor expressed on myeloid cells-2 (TREM2) is a surface receptor with anti-inflammatory properties, kno...

Pediatric Acute Myeloid Leukemia associated S100A9 promotes T cell dysfunction

Grace Ward, Tyler Bruno, Tian Mi et al. Nov 03, 2025 pp. 1725-1725 10.1182/blood-2025-1725

Abstract Despite immunotherapy revolutionizing cancer treatment, myeloid malignancies have remained largely refractory to T cell-based strat...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page